1
|
Webb EW, Cheng K, Winton WP, Klein BJ, Bowden GD, Horikawa M, Liu SW, Wright JS, Verhoog S, Kalyani D, Wismer M, Krska SW, Sanford MS, Scott PJ. Development of High-Throughput Experimentation Approaches for Rapid Radiochemical Exploration. J Am Chem Soc 2024; 146:10581-10590. [PMID: 38580459 PMCID: PMC11099536 DOI: 10.1021/jacs.3c14822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2024]
Abstract
Positron emission tomography is a widely used imaging platform for studying physiological processes. Despite the proliferation of modern synthetic methodologies for radiolabeling, the optimization of these reactions still primarily relies on inefficient one-factor-at-a-time approaches. High-throughput experimentation (HTE) has proven to be a powerful approach for optimizing reactions in many areas of chemical synthesis. However, to date, HTE has rarely been applied to radiochemistry. This is largely because of the short lifetime of common radioisotopes, which presents major challenges for efficient parallel reaction setup and analysis using standard equipment and workflows. Herein, we demonstrate an effective HTE workflow and apply it to the optimization of copper-mediated radiofluorination of pharmaceutically relevant boronate ester substrates. The workflow utilizes commercial equipment and allows for rapid analysis of reactions for optimizing reactions, exploring chemical space using pharmaceutically relevant aryl boronates for radiofluorinations, and constructing large radiochemistry data sets.
Collapse
Affiliation(s)
- E. William Webb
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
| | - Kevin Cheng
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
| | - Wade P. Winton
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
| | - Brandon J.C. Klein
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 North University Avenue, Ann Arbor, Michigan 48109, United States
| | - Gregory D. Bowden
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tuebingen, Tuebingen 72074, Germany
- Cluster of Excellence iFIT (EXC 2180) “Image-Guided and Functionally Instructed Tumor Therapies”, Eberhard Karls University, Tuebingen 72074, Germany
| | - Mami Horikawa
- Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, United States
| | - S. Wendy Liu
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
| | - Jay S. Wright
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
| | - Stefan Verhoog
- Translational Imaging, Merck and Co., Inc., West Point, PA 19486, United States
| | - Dipannita Kalyani
- Discovery Chemistry, Merck Research Laboratories, Merck and Co., Inc., Rahway, NJ 07065, United States
| | - Michael Wismer
- Discovery Chemistry, Merck Research Laboratories, Merck and Co., Inc., Rahway, NJ 07065, United States
| | - Shane W. Krska
- Discovery Chemistry, Merck Research Laboratories, Merck and Co., Inc., Rahway, NJ 07065, United States
| | - Melanie S. Sanford
- Department of Chemistry, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, United States
| | - Peter J.H. Scott
- Department of Radiology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, Michigan 48109, United States
- Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 North University Avenue, Ann Arbor, Michigan 48109, United States
| |
Collapse
|
2
|
Jones J, Do V, Lu Y, van Dam RM. Accelerating radiochemistry development: Automated robotic platform for performing up to 64 droplet radiochemical reactions in a morning. CHEMICAL ENGINEERING JOURNAL (LAUSANNE, SWITZERLAND : 1996) 2023; 468:143524. [PMID: 37576334 PMCID: PMC10421640 DOI: 10.1016/j.cej.2023.143524] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
The growing discovery and development of novel radiopharmaceuticals and radiolabeling methods requires an increasing capacity for radiochemistry experiments. However, such studies typically rely on radiosynthesizers designed for clinical batch production rather than research, greatly limiting throughput. Two general solutions are being pursued to address this: developing new synthesis optimization algorithms to minimize how many experiments are needed, and developing apparatus with enhanced experiment throughput. We describe here a novel high-throughput system based on performing arrays of droplet-based reactions at 10 μL volume scale in parallel. The automatic robotic platform can perform a set of 64 experiments in ~3 h (from isotope loading to crude product, plus sampling onto TLC plates), plus ~1 h for off-line radio-TLC analysis and radioactivity measurements, rather than the weeks or months that would be needed using a conventional system. We show the high repeatability and low crosstalk of the platform and demonstrate optimization studies for two 18F-labeled tracers. This novel automated platform greatly increases the practicality of performing arrays of droplet reactions by eliminating human error, vastly reducing tedium and fatigue, minimizing radiation exposure, and freeing up radiochemist time for other intellectually valuable pursuits.
Collapse
Affiliation(s)
- Jason Jones
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA),Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, UCLA, US
| | - Viviann Do
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA),Los Angeles, CA, USA
- Department of Biochemistry, UCLA, USA
| | - Yingqing Lu
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA),Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, UCLA, US
| | - R Michael van Dam
- Crump Institute of Molecular Imaging, University of California Los Angeles (UCLA),Los Angeles, CA, USA
- Physics and Biology in Medicine Interdepartmental Graduate Program, UCLA, USA
- Department of Molecular & Medical Pharmacology, David Geffen School of Medicine, UCLA, US
- Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, UCLA, USA
| |
Collapse
|
3
|
Goel M, Mackeyev Y, Krishnan S. Radiolabeled nanomaterial for cancer diagnostics and therapeutics: principles and concepts. Cancer Nanotechnol 2023; 14:15. [PMID: 36865684 PMCID: PMC9968708 DOI: 10.1186/s12645-023-00165-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Accepted: 02/13/2023] [Indexed: 03/01/2023] Open
Abstract
In the last three decades, radiopharmaceuticals have proven their effectiveness for cancer diagnosis and therapy. In parallel, the advances in nanotechnology have fueled a plethora of applications in biology and medicine. A convergence of these disciplines has emerged more recently with the advent of nanotechnology-aided radiopharmaceuticals. Capitalizing on the unique physical and functional properties of nanoparticles, radiolabeled nanomaterials or nano-radiopharmaceuticals have the potential to enhance imaging and therapy of human diseases. This article provides an overview of various radionuclides used in diagnostic, therapeutic, and theranostic applications, radionuclide production through different techniques, conventional radionuclide delivery systems, and advancements in the delivery systems for nanomaterials. The review also provides insights into fundamental concepts necessary to improve currently available radionuclide agents and formulate new nano-radiopharmaceuticals.
Collapse
Affiliation(s)
- Muskan Goel
- Amity School of Applied Sciences, Amity University, Gurugram, Haryana 122413 India
| | - Yuri Mackeyev
- Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX 77030 USA
| | - Sunil Krishnan
- Vivian L. Smith Department of Neurosurgery, University of Texas Health Science Center, Houston, TX 77030 USA
| |
Collapse
|
4
|
Lecomte F, Aerts J, Plenevaux A, Defraiteur C, Chapuis-Hugon F, Rozet E, Chiap P, Luxen A, Pichon V, Hubert P, Hubert C. Performance evaluation of a MIP for the MISPE-LC determination of p-[ 18F]MPPF and a potential metabolite in human plasma. J Pharm Biomed Anal 2020; 180:113015. [PMID: 31865206 DOI: 10.1016/j.jpba.2019.113015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2019] [Revised: 10/11/2019] [Accepted: 11/26/2019] [Indexed: 10/25/2022]
Abstract
Within the family of serotonin (5-HT) receptors, the 5-HT1A subtype is particularly interesting as it may be involved in various physiological processes or psychological disorders. The p-[18F]MPPF, a highly selective 5-HT1A antagonist, is used for in vivo studies in human or animal by means of positron emission tomography (PET) [1]. In order to selectively extract p-[18F]MPPF and its main metabolites from plasma, molecularly imprinted polymer (MIP) was prepared against these compounds by using the p-MPPF as template. For the control of the selectivity, non-imprinted polymer (NIP) was also synthesized without template. The MIP sorbent, packed in disposable extraction cartridges (DECs), was then evaluated as molecularly imprinted solid-phase extraction (MISPE) prior to the LC determination. The conditions of extraction were evaluated in order to obtain the highest selective retention of the p-[18F]MPPF and its metabolites on this MIP. The MIP selectivity was exploited in the loading and washing steps by adjusting the pH of plasma samples at a suitable value and by selecting mixtures for the washing step to limit the contribution of non-specific interactions. Other important parameters involved in the conditioning and elution steps were also studied. Finally, a pre-validation was carried out with optimal extraction conditions to demonstrate the performance of this MISPE-LC method as a generic method in the context of evaluation of new MISPE for p-[18F]MPPF and its potential for metabolites extraction from human plasma.
Collapse
Affiliation(s)
- F Lecomte
- University of Liège (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium
| | - J Aerts
- University of Liège (ULiege), GIGA-CRC In VIVO Imaging, Liège, Belgium
| | - A Plenevaux
- University of Liège (ULiege), GIGA-CRC In VIVO Imaging, Liège, Belgium
| | - C Defraiteur
- University of Liège (ULiege), GIGA-CRC In VIVO Imaging, Liège, Belgium
| | - F Chapuis-Hugon
- Dept of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), UMR CBI 8231 (CNRS-ESPCI Paris), ESPCI Paris, PSL University, Paris, France
| | - E Rozet
- Pharmalex, Mont-St-Guibert, Belgium
| | - P Chiap
- Academic Hospital of Liège, Department of Toxicology, GLP-AEPT Unit, CIRM, Liège, Belgium
| | - A Luxen
- University of Liège (ULiege), GIGA-CRC In VIVO Imaging, Liège, Belgium
| | - V Pichon
- Dept of Analytical, Bioanalytical Sciences and Miniaturization (LSABM), UMR CBI 8231 (CNRS-ESPCI Paris), ESPCI Paris, PSL University, Paris, France; Sorbonne Université, Paris, France
| | - Ph Hubert
- University of Liège (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium
| | - C Hubert
- University of Liège (ULiege), CIRM, Laboratory of Pharmaceutical Analytical Chemistry, Liège, Belgium.
| |
Collapse
|
5
|
Vermeulen K, Vandamme M, Bormans G, Cleeren F. Design and Challenges of Radiopharmaceuticals. Semin Nucl Med 2019; 49:339-356. [PMID: 31470930 DOI: 10.1053/j.semnuclmed.2019.07.001] [Citation(s) in RCA: 58] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
This review describes general concepts with regard to radiopharmaceuticals for diagnostic or therapeutic applications that help to understand the specific challenges encountered during the design, (radio)synthesis, in vitro and in vivo evaluation and clinical translation of novel radiopharmaceuticals. The design of a radiopharmaceutical requires upfront decisions with regard to combining a suitable vector molecule with an appropriate radionuclide, considering the type and location of the molecular target, the desired application, and the time constraints imposed by the relatively short half-life of radionuclides. Well-designed in vitro and in vivo experiments allow nonclinical validation of radiotracers. Ultimately, in combination with a limited toxicology package, the radiotracer becomes a radiopharmaceutical for clinical evaluation, produced in compliance with regulatory requirements for medicines for intravenous (IV) injection.
Collapse
Affiliation(s)
- Koen Vermeulen
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium
| | - Mathilde Vandamme
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium
| | - Guy Bormans
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium.
| | - Frederik Cleeren
- Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium
| |
Collapse
|
6
|
Ha NS, Sadeghi S, van Dam RM. Recent Progress toward Microfluidic Quality Control Testing of Radiopharmaceuticals. MICROMACHINES 2017; 8:E337. [PMID: 30400527 PMCID: PMC6190332 DOI: 10.3390/mi8110337] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 11/08/2017] [Accepted: 11/18/2017] [Indexed: 01/18/2023]
Abstract
Radiopharmaceuticals labeled with short-lived positron-emitting or gamma-emitting isotopes are injected into patients just prior to performing positron emission tomography (PET) or single photon emission tomography (SPECT) scans, respectively. These imaging modalities are widely used in clinical care, as well as in the development and evaluation of new therapies in clinical research. Prior to injection, these radiopharmaceuticals (tracers) must undergo quality control (QC) testing to ensure product purity, identity, and safety for human use. Quality tests can be broadly categorized as (i) pharmaceutical tests, needed to ensure molecular identity, physiological compatibility and that no microbiological, pyrogenic, chemical, or particulate contamination is present in the final preparation; and (ii) radioactive tests, needed to ensure proper dosing and that there are no radiochemical and radionuclidic impurities that could interfere with the biodistribution or imaging. Performing the required QC tests is cumbersome and time-consuming, and requires an array of expensive analytical chemistry equipment and significant dedicated lab space. Calibrations, day of use tests, and documentation create an additional burden. Furthermore, in contrast to ordinary pharmaceuticals, each batch of short-lived radiopharmaceuticals must be manufactured and tested within a short period of time to avoid significant losses due to radioactive decay. To meet these challenges, several efforts are underway to develop integrated QC testing instruments that automatically perform and document all of the required tests. More recently, microfluidic quality control systems have been gaining increasing attention due to vastly reduced sample and reagent consumption, shorter analysis times, higher detection sensitivity, increased multiplexing, and reduced instrumentation size. In this review, we describe each of the required QC tests and conventional testing methods, followed by a discussion of efforts to directly miniaturize the test or examples in the literature that could be implemented for miniaturized QC testing.
Collapse
Affiliation(s)
- Noel S Ha
- Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
| | - Saman Sadeghi
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
| | - R Michael van Dam
- Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, CA 90095, USA.
- Crump Institute for Molecular Imaging and Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90095, USA.
| |
Collapse
|
7
|
Kryza D, Janier M. Radio-UHPLC: a tool for rapidly determining the radiochemical purity of technetium-99m radiopharmaceuticals? Appl Radiat Isot 2013; 78:72-6. [PMID: 23681064 DOI: 10.1016/j.apradiso.2013.04.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2012] [Revised: 02/26/2013] [Accepted: 04/05/2013] [Indexed: 11/17/2022]
Abstract
Determining the radiochemical purity (RCP) of technetium-99m ((99m)Tc) radiopharmaceuticals using the method described in the package insert is a time-consuming process, requiring particular attention in order to achieve accurate RCP results. The purpose of this study was to evaluate whether radio-ultra high performance liquid chromatography (radio-UHPLC) may be an alternative method for RCP testing of (99m)Tc-tetrofosmin, (99m)Tc-MAG3 and (99m)Tc-sestamibi. Results obtained using radio-UHPLC were in excellent agreement with the standard method, with total analysis time being reduced to less than 3 min.
Collapse
Affiliation(s)
- David Kryza
- LPMCL UMR 5620 CNRS-Université Claude Bernard Lyon 1, Villeurbanne, France.
| | | |
Collapse
|
8
|
Evaluation of an unshielded luminescence flow-through radio-HPLC detector for LC quality control and preparation of PET radiopharmaceuticals. Appl Radiat Isot 2013; 73:84-9. [DOI: 10.1016/j.apradiso.2012.10.015] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Revised: 10/12/2012] [Accepted: 10/17/2012] [Indexed: 11/20/2022]
|
9
|
Sun X, Gan H, Qiao J, Zhu L, Liu Y, Zhong J. Rapid Detection of the Residual Kryptofix 2.2.2 Levels in [18F]-Labeled Radiopharmaceuticals by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry. ANAL LETT 2011. [DOI: 10.1080/00032719.2010.512679] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|